Bibliography
- PASTOREKOVA S, PASTOREK J: Cancer-related carbonic anhydrase isozymes and their inhibition. In: Carbonic Anhydrase — Its Inhibitors and Activators. Supuran CT, Scozzafava A, Conway J. (Eds) CRC Press, Boca Raton (FL), USA (2004):253–280.
- ••Excellent review on the involvement ofCAs in tumorigenesis, and their inhibition as a means of therapeutic use of sulfonamides targeting the tumour-associated CA IX and XII.
- SCOZZAFAVA A, OWA T, MASTROLORENZO A. SUPURAN CT: Anticancer and antiviral sulfonamides. Curr. Med. Chem. (2003) 10:925–953.
- ••Detailed review on anticancersulfonamides, including CA inhibitors.
- SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev. (2003) 23:146–189.
- ••Detailed review on CA inhibitors.
- SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. Patents (2004) 14:667–702.
- ••Detailed review on therapeutic applications of CA inhibitors
- PASTOREKOVA S, PARKKILA S, PASTOREK J, SUPURAN CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enz Inhib. Med. Chem. (2004) 19:199–229.
- ••Excellent review of CA research
- ROBERTSON N, POTTER C, HARRIS AL: Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. (2004) 64:6160–6165.
- POTTER CP, HARRIS AL: Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer (2003) 89:2–7.
- VULLO D, FRANCHI M, GALLORI E et al.: Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. (2003) 13:1005–1009.
- ••The first study on inhibition of thetumour-associated transmembrane CA IX isozyme with a large series of aromatic and heterocyclic sulfonamides.
- CASEY JR, MORGAN PE, VULLO D, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. (2004) 47:2337–2347.
- ••Detailed study of inhibitors that mayselectively target CA IX, due to their membrane-impermeability and high affinity for this clinically relevant isozyme.
- PASTOREKOVA S, CASINI A, SCOZZAFAVA A, VULLO D, PASTOREK J, SUPURAN CT: Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14:869–873.
- ••The first membrane impermeant and verypotent CA IX inhibitors reported.